AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn dealAstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the Share XAZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn dealhttps://pharmaphorum.com/news/az-gets-closer-to-ionis-licensing-amyloidosis-drug-in-3-6bn-deal/
COVID booster shots increase immunity, trial showsA trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body’s Share XCOVID booster shots increase immunity, trial showshttps://pharmaphorum.com/news/covid-booster-shots-increase-immunity-trial-shows/
Did AZ scupper Sobi’s $8bn private equity buyout?An $8 billion attempt by two private equity companies to acquire Swedish rare disease specialist Sobi and take Share XDid AZ scupper Sobi’s $8bn private equity buyout?https://pharmaphorum.com/news/did-az-scupper-sobis-8bn-private-equity-buyout/
AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer Share XAZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1https://pharmaphorum.com/news/az-eyes-fda-verdict-on-lynparza-in-adjuvant-breast-cancer-in-q1/
Pharma pledges rapid response to Omicron COVID variantWith governments around the world announcing measures to curb the new B.1.1.529 variant of COVID-19 – now christened Share XPharma pledges rapid response to Omicron COVID varianthttps://pharmaphorum.com/news/pharma-pledges-rapid-response-to-omicron-covid-variant/
UK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer firstGenomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year announced that support for Share XUK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer firsthttps://pharmaphorum.com/patients/public-approval-whole-genome-sequencing-newborn-screenings-uk-wide-rollout/
AstraZeneca cuts the ribbon on its $1bn R&D lab in CambridgeAfter years of delays and rising costs, AstraZeneca has formally unveiled its $1 billion R&D facility in Cambridge, Share XAstraZeneca cuts the ribbon on its $1bn R&D lab in Cambridgehttps://pharmaphorum.com/news/astrazeneca-cuts-the-ribbon-on-its-1bn-rd-lab-in-cambridge/
The Covid cash cow – a look at the Covid vaccine sales figuresThe race to find and bring vaccines to market to fight Covid was impressive. So too are the Share XThe Covid cash cow – a look at the Covid vaccine sales figureshttps://pharmaphorum.com/sales-marketing/phamra-covid-vaccine-cash-cow/
AZ, Moderna say mRNA drug is promising in heart failureModerna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of Share XAZ, Moderna say mRNA drug is promising in heart failurehttps://pharmaphorum.com/news/az-moderna-say-mrna-drug-is-promising-in-heart-failure/
